Apr 18, 2024 10:53 JST

Source: Eisai

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
As a Part of FY2024 Commendation For Science and Technology by MEXT

TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms” has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) grants this award to individuals who have made remarkable achievements regarding research, development, and knowledge enhancement in the field of science and technology, with the aim of encouraging those who engage in the field and raising the standard of Japanese science and technology. This award is presented to individuals who have completed original research and development projects with high potential to contribute to the advancement of science and technology in Japan.

Teiji Kimura, Ph.D., Senior Group Officer of Eisai, and Prof. Takeshi Iwatsubo, Graduate School of Medicine and Faculty of Medicine, the University of Tokyo, were awarded this prize in recognition of the breakthrough achieved through the creation of the anti-Aβ protofibril antibody lecanemab, that was accomplished by a combination of the efforts of academia, in particular the establishment of the theoretical basis for Aβ- targeted therapy based on functional genetics and the development of a clinical trial environment incorporating imaging and biomarkers based on large-scale clinical observational studies such as J-ADNI (Japanese Alzheimer's Disease Neuroimaging Initiative), and our corporate commitment to anti-Aβ drug discovery research.

Award Theme

The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms

Awardees

Prof. Takeshi Iwatsubo (Graduate School of Medicine and Faculty of Medicine, the University of Tokyo) Teiji Kimura (Global Alzheimer's Disease Head, Global Collaboration Network Lead, Senior Group Officer, Eisai Co., Ltd.)

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
 
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
 
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
December 04 2025 17:36 JST
 
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
December 03 2025 17:19 JST
 
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
December 02 2025 23:01 JST
 
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
 
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
More Press release >>

Latest Press Release


More Latest Release >>